Drug

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea
Auto-immuneEverest Medicines

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea

Everest Medicines (HKG: 1952) announced that the Taiwan Food and Drug Administration (TFDA) has approved the New Drug Application for Velsipity film‑coated tablets (etrasimod) for the treatment of adult patients…

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Johnson & Johnson Secures FDA Approval for INLEXZO, a Ground‑breaking Intravesical System for Bladder Cancer
CancerJ&J

Johnson & Johnson Secures FDA Approval for INLEXZO, a Ground‑breaking Intravesical System for Bladder Cancer

Kexing Biopharm Secures Global Rights to Humanwell PuraCap’s Nintedanib
Generic drugsHumanwell Healthcare

Kexing Biopharm Secures Global Rights to Humanwell PuraCap’s Nintedanib

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer
Clinical trial approval / initiationMulti-specific antibodies

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer

Novartis Expands Iptacopan Approval to IgA Nephropathy in China
NovartisNYSE: NVS

Novartis Expands Iptacopan Approval to IgA Nephropathy in China

Show More